



LUPIN LIMITED

Registered Office: 3rd Floor, Kalpataru Inspire, Off. Western Express Highway, Santacruz (East), Mumbai 400 055.

Corporate Identity Number: L24100MH1983PLC029442

Tel: (91-22) 6640 2323

E-mail: info@lupin.com

Website: www.lupin.com

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026

Particulars	₹ (in million)			
	Quarter Ended 30/06/2026 (Unaudited)	Quarter Ended 31/03/2026 (Audited) (Refer note 9)	Quarter Ended 30/06/2025 (Unaudited)	Year Ended 31/03/2026 (Audited)
1) Revenue from operations				
a) Sales / income from operations	82,172.3	73,919.1	61,637.5	274,875.4
b) Other operating income	596.6	827.5	1,045.9	4,704.9
Total Revenue from operations	82,768.9	74,746.6	62,683.4	279,580.3
2) Other income	1,303.2	1,407.1	790.4	4,244.5
3) Total income (1+2)	84,072.1	76,153.7	63,473.8	283,824.8
4) Expenses				
a) Cost of materials consumed	13,116.6	12,313.0	11,266.3	46,219.0
b) Purchases of stock-in-trade	8,422.7	7,084.1	7,139.5	28,670.1
c) Changes in Inventories of finished goods, work-in-progress and stock-in-trade [(increase) / decrease]	(646.9)	(880.8)	(686.5)	(1,624.5)
d) Employee benefits expense	13,830.0	12,426.9	10,830.0	45,745.3
e) Finance costs	1,096.4	1,201.6	917.6	4,344.9
f) Depreciation, amortisation and impairment expense (Refer note 8)	4,528.5	4,467.9	2,989.8	13,755.0
g) Other expenses	23,412.0	22,092.7	17,720.4	78,975.1
h) Net loss / (gain) on foreign currency transactions	139.0	(3,145.1)	(858.7)	(6,564.7)
Total expenses	63,898.3	55,560.3	49,318.4	209,520.2
5) Profit / (Loss) before share of profit of joint venture and tax (3-4)	20,173.8	20,593.4	14,155.4	74,304.6
6) Share of loss from joint venture (net of tax)	(0.2)	-	-	-
7) Profit / (Loss) before tax and exceptional items (5+6)	20,173.6	20,593.4	14,155.4	74,304.6
8) Exceptional items [income/(expense)] (Refer note 6)	-	(1,313.4)	-	(5,579.1)
9) Profit / (Loss) before tax (7+8)	20,173.6	19,280.0	14,155.4	68,725.5
10) Tax expense				
Current tax (net)	9,843.9	5,079.2	4,908.9	15,273.5
Deferred tax (net)	(3,840.1)	(485.9)	(2,968.1)	(102.7)
Total tax expense	6,003.8	4,593.3	1,940.8	15,170.8
11) Profit / (Loss) after tax (9-10)	14,169.8	14,686.7	12,214.6	53,554.7
12) Other Comprehensive Income / (Loss)				
(a) (i) Items that will not be reclassified subsequently to profit or loss	(0.8)	5.2	(103.5)	(63.9)
(ii) Income tax relating to items that will not be reclassified subsequently to profit or loss	1.1	(19.3)	36.2	1.1
(b) (i) Items that will be reclassified subsequently to profit or loss	521.7	517.6	1,694.9	4,195.6
(ii) Income tax relating to items that will be reclassified subsequently to profit or loss	(166.9)	139.1	(25.4)	271.2
Other comprehensive Income / (Loss), net of tax	355.1	642.6	1,602.2	4,404.0
13) Total comprehensive Income / (Loss), net of tax (11+12)	14,524.9	15,329.3	13,816.8	57,958.7
14) Profit / (Loss) attributable to :				
Owners of the Company	14,150.0	14,603.4	12,190.3	53,328.4
Non-Controlling Interest of the Company	19.8	83.3	24.3	226.3
Profit / (Loss) for the period	14,169.8	14,686.7	12,214.6	53,554.7
15) Other Comprehensive Income / (Loss) attributable to:				
Owners of the Company	361.3	616.4	1,582.7	4,356.3
Non-Controlling Interest of the Company	(6.2)	26.2	19.5	47.7
Other Comprehensive Income / (Loss) for the period	355.1	642.6	1,602.2	4,404.0
16) Total Comprehensive Income / (Loss) attributable to:				
Owners of the Company	14,511.3	15,219.8	13,773.0	57,684.7
Non-Controlling Interest of the Company	13.6	109.5	43.8	274.0
Total Comprehensive Income / (Loss) for the period	14,524.9	15,329.3	13,816.8	57,958.7
17) Paid up equity share capital (Face value of ₹ 2/- each)	914.5	914.4	913.5	914.4
18) Other Equity				223,568.3
19) Earnings per share (Face value of ₹ 2/- each) (Not annualised for the quarters)				
(A) Before exceptional items				
a) Basic (in ₹)	30.95	34.83	26.70	128.45
b) Diluted (in ₹)	30.89	34.75	26.62	128.11
(B) After exceptional items				
a) Basic (in ₹)	30.95	31.96	26.70	116.75
b) Diluted (in ₹)	30.89	31.89	26.62	116.44

See accompanying notes to the consolidated financial results.

continued on Page 2..

Segment Information				
(₹ in million)				
Particulars	Quarter Ended 30/06/2026 (Unaudited)	Quarter Ended 31/03/2026 (Audited) (Refer note 9)	Quarter Ended 30/06/2025 (Unaudited)	Year Ended 31/03/2026 (Audited)
1) Revenue				
a) Pharmaceuticals	82,343.5	74,347.4	62,364.1	278,123.6
b) Others	430.3	404.7	322.8	1,473.9
Total	82,773.8	74,752.1	62,686.9	279,597.5
Less: Inter segment revenue	4.9	5.5	3.5	17.2
Total revenue from operations	82,768.9	74,746.6	62,683.4	279,580.3
2) Results				
a) Pharmaceuticals	20,605.6	19,771.0	14,578.4	70,502.7
b) Others	(432.0)	(491.0)	(423.0)	(1,777.2)
Total profit before tax (after exceptional items)	20,173.6	19,280.0	14,155.4	68,725.5
3) Assets				
a) Pharmaceuticals	406,033.0	381,286.0	318,909.9	381,286.0
b) Others	2,354.6	2,394.6	2,229.4	2,394.6
Total	408,387.6	383,680.6	321,139.3	383,680.6
Less: Inter segment assets	216.5	32.3	3,522.7	32.3
Total assets	408,171.1	383,648.3	317,616.6	383,648.3
4) Liabilities				
a) Pharmaceuticals	167,384.1	157,462.2	129,854.8	157,462.2
b) Others	1,194.8	1,084.7	3,070.0	1,084.7
Total	168,578.9	158,546.9	132,924.8	158,546.9
Less: Inter segment liabilities	216.6	32.3	2,115.8	32.3
Total liabilities	168,362.3	158,514.6	130,809.0	158,514.6
NOTES:				
1 The above Consolidated Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on August 06, 2026. The Statutory Auditors of the Company have carried out limited review of the above Consolidated Financial Results pursuant to Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.				
2 The Consolidated Financial Results include the financial results of the subsidiaries, Lupin Pharmaceuticals, Inc. - U.S.A., Lupin Australia Pty Limited - Australia, Nanomi B.V. - Netherlands, Pharma Dynamics (Proprietary) Limited - South Africa, Hormosan Pharma GmbH - Germany, Multicare Pharmaceuticals Philippines Inc. - Philippines, Lupin Atlantis Holdings SA - Switzerland, Lupin Healthcare (UK) Limited - U.K., Lupin Pharma Canada Limited - Canada, Generic Health Pty Limited - Australia, Lupin Mexico S.A. de C.V. - Mexico, Lupin Philippines Inc. - Philippines, Lupin Diagnostics Limited - India, Generic Health SDN. BHD. - Malaysia, Lupin Inc. - U.S.A., Laboratorios Grin S.A. de C.V. - Mexico, Medquímica Industria Farmaceutica LTDA - Brazil, Novel Laboratories, Inc.- U.S.A., Lupin Research Inc. - U.S.A., Lupin Management Inc. - U.S.A., Lupin Europe GmbH - Germany, Lupin Biologics Limited - India, Lupin Oncology Inc. - U.S.A., Lupin Digital Health Limited - India, Avenue Coral Springs LLC - U.S.A., Southern Cross Pharma Pty Ltd - Australia, Lupin Life Sciences Limited - India, Lupin Manufacturing Solutions Limited - India, Medisol S.A.S. - France, Lupin Lanka (Private) Ltd. - Sri Lanka, Lupin NZ Ltd. - New Zealand, Lupinlife Consumer Healthcare Limited - India, Renaissance Pharma Limited - U.K. (w.e.f. April 02, 2025), VISUfarma B.V. - Netherlands (w.e.f. April 01, 2026), VISUfarma UK Limited - U.K. (w.e.f. April 01, 2026), VISUfarma SPA - Italy (w.e.f. April 01, 2026), IRIS Bidco SAS - France (w.e.f. April 01, 2026), IRIS BidCo Srl - Italy (w.e.f. April 01, 2026), VISUfarma Espana SL, Spain (w.e.f. April 01, 2026), Laboratorios Nicox SLU, Spain (w.e.f. April 01, 2026), Lupin (Thailand) Limited, Thailand (w.e.f. April 17, 2026) and a joint venture, YL Biologics Limited - Japan.				
3 The Consolidated Financial Statements are prepared in accordance with Ind AS 110 "Consolidated Financial Statements" and Ind AS 28 "Investments in Associates and Joint Ventures".				
4 During the quarter ended June 30, 2026, 53,425 equity shares of ₹ 2/- each, fully paid-up, were allotted upon exercise of the vested stock options pursuant to the Lupin Employees Stock Option Plans (ESOPs), resulting in an increase in the paid-up share capital by ₹ 0.1 million and securities premium account by ₹ 76.9 million.				
5 During the quarter ended June 30, 2026, acquisition of wholly owned subsidiary VISUfarma B.V., Netherlands was concluded by Nanomi B.V., Netherlands on April 01, 2026, with total consideration of ₹ 20,902.7 million (Euro 192.8 million). Fair value of intangibles acquired ₹ 15,971.1 million, deferred tax liability ₹ 3,992.8 million, Goodwill ₹ 6,030.2 million has been provisionally accounted based on report of independent valuer. The acquisition related costs are accounted in "Other expenses".				
6 Exceptional items				
a. The Group is exposed to multiple civil lawsuits alleging anticompetitive behavior related to certain products and possible violation of federal and state antitrust laws. These lawsuits were combined into the collection of similar cases referred to as In Re Generic Pharmaceuticals Antitrust Litigation. Such litigation are often resolved through settlement agreements. During the quarter ended March 31, 2026; the Group has based on best estimate, created a provision, of ₹ 1,323.1 million (USD 15.8 million), resulting in cumulative provision of ₹ 5,816.9 million (USD 65.8 million) at year ended March 31, 2026 related to antitrust litigation matters. In April 2026, Lupin Pharmaceuticals, Inc., U.S.A., a wholly owned subsidiary of the Group, settled one of the ongoing antitrust matters for an amount of ₹ 2,654.1 million (USD 30.0 million) without admission of liability or wrongdoing. The remaining provision continues to be carried by the Group towards future settlements related to similar cases.				
b. On February 09, 2026, Lupin Limited and its subsidiary entered into a settlement agreement with Astellas towards ongoing dispute related to Mirabegron ER Tablets a generic version of Myrbetriq ER Tablets in US markets. In respect of the same, Lupin Pharmaceuticals, Inc., U.S.A. paid ₹ 8,475.5 million (USD 90.0 million), which includes ₹ 7,110.8 million (USD 75.0 million) as Prepaid Option and ₹ 1,364.7 million (USD 15.0 million) as one-time payment towards the settlement. During the year ended March 31, 2026, the Group has expensed out ₹ 1,364.7 million (USD 15.0 million) and has capitalised the balance amount towards Prepaid Option.				
c. The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four labour codes as follows: Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "New Labour Codes"). The New Labour Codes are effective from November 21, 2025 and introduce changes that include, among other things, setting a uniform definition of wages. The Group has assessed the implications of the New Labour Codes and has recognized an incremental cost of ₹ 512.2 million during the year ended March 31, 2026. The Group continues to monitor the developments pertaining to the New Labour Codes and the impact, if any, will be accounted in accordance with applicable accounting standards.				
d. During the year ended March 31, 2026, the Group entered into a settlement agreement with an income of ₹ 873.7 million (USD 10.0 million).				
e. During the year ended March 31, 2026, the Group has received an arbitration award, consequently accounted an income of ₹ 603.2 million (USD 6.9 million) and a reversal of expense provision of ₹ 611.6 million (USD 7.0 million).				

continued on Page 3..

- 7 During the quarter ended June 30, 2025, the Company through its wholly owned step-down subsidiary, Lupin Healthcare (UK) Limited, U.K., acquired 100% equity share capital of Renascience Pharma Limited, U.K., for a consideration of ₹ 1,361.6 million (GBP 12.3 million). Fair value of intangibles acquired ₹ 1,239.4 million, deferred tax liability ₹ 309.8 million, Goodwill ₹ 325.9 million has been accounted based on report of independent valuer. The acquisition related costs are accounted in "Other expenses".
- 8 During the quarter and year ended March 31, 2026, the Group has recognised an impairment charge of ₹ 879.1 million and ₹ 1,130.1 million respectively related to certain capital work-in-progress, intangible assets and intangible assets under development.
- 9 The figures for the quarter ended March 31, 2026 are the balancing figures between audited figures in respect of the previous full financial year and the unaudited published year-to-date figures up to the third quarter ended December 31, 2025. The year-to-date figures up to the third quarter ended December 31, 2025 were only subject to Limited Review and not audited.

By order of the Board
For Lupin Limited

Nilesh
Deshbandhu
Gupta

Digitally signed
by Nilesh
Deshbandhu
Gupta
Date: 2026.08.06
18:49:24 +05'30'

Nilesh D. Gupta
Managing Director
DIN: 01734642

Place : Zurich
Date : August 06, 2026

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM
CONSOLIDATED FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF
LUPIN LIMITED**

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **LUPIN LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net loss after tax and total comprehensive loss of its one joint venture for the quarter ended June 30, 2026 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of entities mentioned in **Annexure I** to this report.

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial information of 17 subsidiaries included in the consolidated unaudited financial results, whose interim financial information reflect total revenues of Rs. 53,604.3 million (before consolidation adjustments) for the quarter ended June 30, 2026, total net loss after tax of Rs. 2,411.0 million (before consolidation adjustments) for the quarter ended June 30, 2026 and total comprehensive loss of Rs. 2,614.8 million (before consolidation adjustments) for the quarter ended June 30, 2026 as considered in the Statement. These interim financial statements have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

These subsidiaries are located outside India whose interim financial statements have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been reviewed by other auditors under generally accepted auditing standards applicable in their respective countries. The Parent's management has converted the interim financial statements of such subsidiaries located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Parent's management. Our conclusion in so far as it relates to the balances and affairs of such subsidiaries located outside India is based on the report of other auditors and the conversion adjustments prepared by the management of the Company and reviewed by us.

Our conclusion on the Statement is not modified in respect of this matter.

7. The consolidated unaudited financial results includes the financial information of 17 subsidiaries which have not been reviewed by their auditors, whose interim financial information reflect total revenue of Rs. 3,894.1 million (before consolidation adjustments) for the quarter ended June 30, 2026, total profit after tax of Rs. 473.5 million (before consolidation adjustments) for the quarter ended June 30, 2026 and total comprehensive income of Rs. 455.7 million (before consolidation adjustments) for the quarter ended June 30, 2026, as considered in the Statement. The consolidated unaudited financial results also includes the Group's share of loss after tax of Rs. 0.2 million for the quarter ended June 30, 2026 and total comprehensive loss of Rs. 5.6 million for the quarter ended June 30, 2026, as considered in the Statement, in respect of 1 joint venture, based on their interim financial information which have not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our conclusion on the Statement is not modified in respect of this matter.

8. The consolidated financial results of the Company for the quarter and year ended March 31, 2026 and for the quarter ended June 30, 2025 included in the Statement, were audited/ reviewed by another auditor who expressed an unmodified opinion/ conclusion on those statements on May 07, 2026 and August 05, 2025 respectively.

Our conclusion on the Statement is not modified in respect of this matter.

9. The figures for the three months ended March 31, 2026 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures upto the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

Our conclusion on the Statement is not modified in respect of this matter.

For **Deloitte Haskins & Sells Chartered Accountants LLP**
Chartered Accountants
(Firm's Registration No. 117364W/W100739)

MOHAMMED
SAIFUDDIN
BENGALI

Digitally signed by
MOHAMMED
SAIFUDDIN BENGALI
Date: 2026.08.06
20:14:53 +05'30'

Mohammed Bengali
(Partner)
(Membership No. 105828)
(UDIN: 26105828CDVBON2993)

Place: Mumbai
Date: August 06, 2026

**ANNEXURE I TO THE INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF
INTERIM CONSOLIDATED FINANCIAL RESULTS**

(Referred to in paragraph 4 under Independent Auditor's Review Report of even date to the Board of Directors of Lupin Limited)

Sr. No.	Name of entities	Relationship
1	Lupin Limited	Parent
2	Lupin Pharmaceuticals, Inc.- USA	Subsidiary
3	Lupin Australia Pty Limited – Australia	Subsidiary
4	Nanomi B.V. – Netherlands	Subsidiary
5	Pharma Dynamics (Proprietary) Limited - South Africa	Subsidiary
6	Multicare Pharmaceuticals Philippines Inc. - Philippines	Subsidiary
7	Lupin Philippines, Inc. – Philippines	Subsidiary
8	Hormosan Pharma GmbH – Germany	Subsidiary
9	Generic Health SDN. BHD. – Malaysia	Subsidiary
10	Lupin Mexico S.A. de C.V. - Mexico	Subsidiary
11	Lupin Inc. - USA	Subsidiary
12	Avenue Coral Springs, LLC – USA	Subsidiary
13	Lupin Oncology Inc. – USA	Subsidiary
14	Lupin Research Inc. – USA	Subsidiary
15	Lupin Management Inc. – USA	Subsidiary
16	Novel Laboratories, Inc. – USA	Subsidiary
17	VISUfarma B.V. - Netherlands (w.e.f. April 01, 2026)	Subsidiary

18	VISUfarma UK Ltd – United Kingdom (w.e.f. April 01, 2026)	Subsidiary
19	Iris BidCo Srl – Italy (w.e.f. April 01, 2026)	Subsidiary
20	Laboratorios Nicox SLU – Spain (w.e.f. April 01, 2026)	Subsidiary
21	VISUfarma España SL - Spain (w.e.f. April 01, 2026)	Subsidiary
22	Iris Bidco SAS – France (w.e.f. April 01, 2026)	Subsidiary
23	VISUfarma SpA - Italy (w.e.f. April 01, 2026)	Subsidiary
24	Lupin Diagnostics Limited - India	Subsidiary
25	Lupin (Thailand) Ltd. - Thailand (Incorporated on April 17, 2026)	Subsidiary
26	Lupin Biologics Limited - India	Subsidiary
27	Lupin Digital Health Limited - India	Subsidiary
28	Lupin Life Sciences Limited - India	Subsidiary
29	Lupin Manufacturing Solutions Limited - India	Subsidiary
30	LupinLife Consumer Healthcare Limited - India	Subsidiary
31	Lupin Atlantis Holdings S.A. - Switzerland	Subsidiary
32	Lupin Europe GmbH – Germany	Subsidiary
33	Medquímica Industria Farmaceutica LTDA - Brazil	Subsidiary
34	Medisol S.A.S. – France	Subsidiary

35	Lupin Pharma Canada Ltd. - Canada	Subsidiary
36	Laboratorios Grin, S.A. de C.V. - Mexico	Subsidiary
37	Lupin Healthcare (UK) Limited - United Kingdom	Subsidiary
38	Renascience Pharma Limited - United Kingdom	Subsidiary
39	Southern Cross Pharma Pty Ltd. - Australia	Subsidiary
40	Generic Health Pty Ltd. - Australia	Subsidiary
41	Lupin NZ Ltd. - New Zealand	Subsidiary
42	Lupin Lanka (Private) Limited - Sri Lanka	Subsidiary
43	YL Biologics Limited - Japan	Joint Venture